SINGAPORE —Sanofi, a leading global pharmaceutical company, has opened a state-of-the-art vaccine production facility in Singapore.
Located in the Tuas Biomedical Park, the US$595 million facility, known as Modulus, represents a major step forward in vaccine manufacturing for the Asia-Pacific region.
It is part of Sanofi’s larger €900 million (US$948 million) investment to build two new Evolutive Vaccine Facilities (EVFs) over the next five years.
The second facility will be situated in Neuville-sur-Saône, France.
The Modulus facility is Sanofi’s first EVF outside of France, highlighting the company’s dedication to advancing vaccine technologies and ensuring global health preparedness.
Designed with cutting-edge modular technology, Modulus can produce a variety of vaccines.
This flexibility allows it to quickly adapt to manufacturing needs, such as producing vaccines for pandemics or responding to other urgent healthcare demands.
One standout feature of the facility is its ability to produce up to four different vaccines or biopharmaceuticals simultaneously.
This capability makes Modulus a valuable resource in the fight against infectious diseases, ensuring a steady supply of critical vaccines even during periods of high demand.
The facility will contribute about 200 jobs to the city-state, including bioprocess engineers, automation specialists and data analysts, and will be fully operational by mid-2026.
Brendan O’Callaghan, Sanofi’s executive vice president for manufacturing and supply, highlighted the EVF’s innovative approach.
He explained that Modulus sets a new standard in vaccine production by combining advanced technology with strategic geographic advantages.
Its ability to quickly scale production up or down provides a critical edge in addressing health emergencies, making it a cornerstone in the global effort to combat future pandemics.
Unlike traditional vaccine manufacturing plants, Modulus offers unparalleled speed and flexibility.
It can work with health authorities to adjust production capacity as needed, even though it does not currently reserve capacity specifically for emergencies.
The opening of the Singapore facility reflects Sanofi’s commitment to strengthening vaccine supply chains and supporting public health globally.
Modulus is expected to play a vital role in addressing current and future healthcare challenges by enhancing regional manufacturing capabilities.
Sign up HERE to receive our email newsletters with the latest news and insights from Africa and around the world, and follow us on our WhatsApp channel for updates.
